Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium

Bernard Lambermont, Anne-Françoise Rousseau, Laurence Seidel, Marie Thys, Jonathan Cavalleri, Pierre Delanaye, J Geoffrey Chase, Pierre Gillet, Benoit Misset, Bernard Lambermont, Anne-Françoise Rousseau, Laurence Seidel, Marie Thys, Jonathan Cavalleri, Pierre Delanaye, J Geoffrey Chase, Pierre Gillet, Benoit Misset

Abstract

Objectives: To compare patient management and outcome during the first and second waves of the coronavirus 2019 pandemic.

Design: Single-center prospective cohort study.

Setting: Tertiary-care University Hospital.

Patients: All adult patients admitted in either the first (from March 15 to May 15, 2020) or second (from October 1 to November 30, 2020) wave of coronavirus disease 2019.

Interventions: None.

Measurements and main results: Primary outcome was 30-day mortality. During the second wave of the coronavirus disease 2019 pandemic, 33 patients (4.8%) were transferred due to overcrowding and excluded from analysis. There were 341 (first wave of the coronavirus disease 2019 pandemic) and 695 (second wave of the coronavirus disease 2019 pandemic) coronavirus disease 2019 patients admitted to the hospital, with median age first wave of the coronavirus disease 2019 pandemic as 68 (57-80) and second wave of the coronavirus disease 2019 pandemic as 71 (60-80) (p = 0.15), and similar admission severity. For the first wave of the coronavirus disease 2019 pandemic versus second wave of the coronavirus disease 2019 pandemic, 30-day mortality was 74/341 (22%) and 98/662 (15%) (p = 0.007). In the ward, 11/341 (3.2%) and 404/662 (61%) received dexamethasone (p < 0.001); 6/341 (2%) and 79/662 (12%) received high-flow nasal oxygen (p < 0.0001); 2/341 (0.6%) and 88/662 (13.3%) received remdesivir (p < 0.0001); 249/341 (73%) and 0/662 (0%) received hydroxychloroquine (p < 0.0001); and 87/341 (26%) and 128/662 (19%) (p = 0.024) patients were transferred to ICU. On ICU admission, median Sequential Organ Failure Assessment was 6 (3-7) and 4 (3-6) (p = 0.02). High-flow nasal oxygen was given to 16/87 (18%) and 102/128 (80%) (p < 0.001); 69/87 (79%) and 56/128 (44%) received mechanical ventilation (p < 0.001) with durations 17 days (10-26 d) and 10 days (5-17 d) (p = 0.01). Median ICU length of stay was 14 days (5-27 d) and 6 days (3-11 d) (p < 0.001). Finally, 16/87 (18%) and 8/128 (6%) received renal replacement therapy (p = 0.0055); and 64/87 (74%) and 51/128 (40%) needed vasopressor support (p < 0.001).

Conclusions: The main therapeutic changes between the first wave of the coronavirus disease 2019 pandemic and the second wave of the coronavirus disease 2019 pandemic were use of steroids, unrestrictive use of high-flow nasal oxygen for hypoxemic patients, and transfer of patients to other geographic areas in the case of ICU overcrowding. These changes were associated with a decrease in 30-day mortality, ICU admission, and organ support.

Keywords: coronavirus disease 2019; corticosteroids; high-flow nasal oxygen; intensive care; mechanical ventilation; remdesivir.

Conflict of interest statement

The authors have disclosed that they do not have any potential conflicts of interest.

Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

Figures

Figure 1.
Figure 1.
Clinical management of coronavirus disease 2019 patients during the first and second waves of the pandemic. HFNO = high-flow nasal oxygen, RR = respiratory rate.

References

    1. Jamil S, Mark N, Carlos G, et al. : Diagnosis and management of COVID-19 disease. Am J Respir Crit Care Med. 2020; 201:P19–P20
    1. Sanders JM, Monogue ML, Jodlowski TZ, et al. : Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA. 2020; 323:1824–1836
    1. Arabi YM, Fowler R, Hayden FG: Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020; 46:315–328
    1. RECOVERY Collaborative Group: Dexamethasone in hospitalized patients with Covid-19. N Eng J Med. 2021; 384:693–704
    1. Sterne JAC, Murthy S, Diaz JV, et al. ; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020; 324:1330–1341
    1. Beigel JH, Tomashek KM, Dodd LE, et al. ; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020; 383:1813–1826
    1. Alhazzani W, Evans L, Alshamsi F, et al. : Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: First update. Crit Care Med. 2021; 49:e219–e234
    1. Murthy S, Gomersall CD, Fowler RA: Care for critically ill patients with COVID-19. JAMA. 2020; 323:1499–1500
    1. Gaeckle NT, Lee J, Park Y, et al. : Aerosol generation from the respiratory tract with various modes of oxygen delivery. Am J Respir Crit Care Med. 2020; 202:1115–1124
    1. Alhazzani W, Møller MH, Arabi YM, et al. : Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020; 46:854–887
    1. Vandromme M, De Pauw R, Serrien B, et al. ; Sciensano: Covid-19 Clinical Hospital Surveillance Report. Available at: . Accessed February 1, 2021
    1. Russell CD, Millar JE, Baillie JK: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395:473–475
    1. Cavalcanti AB, Zampieri FG, Rosa RG, et al. : Hydroxychloroquine with or without Azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020; 383:2041–2052
    1. Horby P, Mafham M, Linsell L, et al. : Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020; 383:2030–2040
    1. Haymet A, Bassi GL, Fraser JF: Airborne spread of SARS-CoV-2 while using high-flow nasal cannula oxygen therapy: Myth or reality? Intensive Care Med. 2020; 46:2248–2251
    1. Bagshaw SM, Wang X, Zygun DA, et al. : Association between strained capacity and mortality among patients admitted to intensive care: A path-analysis modeling strategy. J Crit Care. 2018; 43:81–87
    1. Grasselli G, Tonetti T, Protti A, et al. ; Collaborators. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: A multicentre prospective observational study. Lancet Respir Med. 2020; 8:1201–1208
    1. Prescott HC, Levy MM: Survival from severe coronavirus disease 2019: Is it changing? Crit Care Med. 2021; 49:351–353
    1. Contou D, Fraissé M, Pajot O, et al. : Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave? Crit Care. 2021; 25:3.
    1. Dennis JM, McGovern AP, Vollmer SJ, et al. : Improving survival of critical care patients with coronavirus disease 2019 in England: A national cohort study, March to June 2020. Crit Care Med. 2021; 49:209–214
    1. Bravata DM, Perkins AJ, Myers LJ, et al. : Association of intensive care unit patient load and demand with mortality rates in US Department of Veterans Affairs Hospitals during the COVID-19 pandemic. JAMA Netw Open. 2021; 4:e2034266.
    1. Bellani G, Laffey JG, Pham T, et al. ; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016; 315:788–800

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe